Snhg20-KO Mouse
一般名
Snhg20-KO
製品ID
S-KO-15000
背景情報
C57BL/6JCya
系統ID
KOCMP-76972-Snhg20-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Snhg20-KO Mouse（カタログ番号S-KO-15000）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Snhg20-KO
系統ID
KOCMP-76972-Snhg20-B6J-VA
遺伝子名
製品ID
S-KO-15000
遺伝子別名
2810008D09Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 11
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000149822
NCBIトランスクリプトID
NR_027059
ターゲット領域
Exon 1~2
有効領域の大きさ
~4.8 kb
遺伝子研究の概要
Snhg20, a long noncoding RNA (lncRNA), is a member of the small nucleolar RNA host gene family. LncRNAs with a length >200 nucleotides play crucial roles as initial factors and promoters in different tumors. Snhg20 expresses frequently in various cancers such as hepatocellular carcinoma, ovarian cancer, and colorectal cancer, contributing to cancer development and progression through transcriptional or posttranscriptional modifications [1].
In multiple cancer types, studies have shown significant implications of Snhg20. In hepatocellular carcinoma, knockdown of Snhg20 inhibited cell metastasis and accelerated apoptosis, as it acts as a sponge of miR-5095, which negatively targets MBD1, thus regulating HCC progression [4]. In ovarian cancer, Snhg20 promoted cell proliferation and invasion by sponging miR-217 [5]. In laryngeal squamous cell carcinoma, Snhg20 promoted cell proliferation, migration, and invasion, likely mediated by miR-342-3p and miR-140 [3,6]. In diffuse large B-cell lymphoma, c-MYC-activated Snhg20 accelerated cell proliferation and increased apoptosis resistance via USP14-mediated deubiquitination of β-catenin [7]. In prostate cancer, Snhg20 promoted cell proliferation and migration by acting as a ceRNA to upregulate DDX17 [8]. In lung adenocarcinoma, Snhg20 regulated cell proliferation, invasion, and apoptosis via the miR-342/DDX49 axis [9]. A meta-analysis also indicated that high Snhg20 expression was linked to poorer overall and disease-free survival, as well as advanced clinicopathological features in cancer patients [2].
In conclusion, Snhg20 is a vital lncRNA in multiple human cancers, promoting cancer development and progression through various miRNA-mediated and other molecular mechanisms. These findings from in vitro and in vivo studies (although no KO/CKO mouse models were mentioned in the references) suggest Snhg20 could potentially serve as a biomarker and a therapeutic target for cancers [1-10].
References:
1. Zhao, Wei, Ma, Xiaozhou, Liu, Lina, Wang, Zuomin, Wu, Jie. 2019. SNHG20: A vital lncRNA in multiple human cancers. In Journal of cellular physiology, 234, 14519-14525. doi:10.1002/jcp.28143. https://pubmed.ncbi.nlm.nih.gov/30644099/
2. Zhu, Hanlong, Zhao, Si, Jiao, Ruonan, Li, Quanpeng, Miao, Lin. 2020. Prognostic and clinicopathological significance of SNHG20 in human cancers: a meta-analysis. In Cancer cell international, 20, 304. doi:10.1186/s12935-020-01403-8. https://pubmed.ncbi.nlm.nih.gov/32675944/
3. Xie, Zuozhong, Xiang, Hong, Li, Jingkun, Li, Wei, Tan, Guolin. 2022. SNHG20 promotes the development of laryngeal squamous cell carcinoma via miR-342-3p/MTDH axis. In Heliyon, 8, e10085. doi:10.1016/j.heliyon.2022.e10085. https://pubmed.ncbi.nlm.nih.gov/36033309/
4. Xu, Bin, Li, Chao, Yang, Bin, Wang, Lantian, Lu, Wenjie. 2023. LncRNA SNHG20 silencing inhibits hepatocellular carcinoma progression by sponging miR-5095 from MBD1. In American journal of translational research, 15, 4314-4331. doi:. https://pubmed.ncbi.nlm.nih.gov/37434830/
5. Xing, Xuefeng, An, Ming, Chen, Tonghua. 2021. LncRNA SNHG20 promotes cell proliferation and invasion by suppressing miR-217 in ovarian cancer. In Genes & genomics, 43, 1095-1104. doi:10.1007/s13258-021-01138-4. https://pubmed.ncbi.nlm.nih.gov/34302635/
6. Li, Y, Xu, J, Guo, Y-N, Yang, B-B. . LncRNA SNHG20 promotes the development of laryngeal squamous cell carcinoma by regulating miR-140. In European review for medical and pharmacological sciences, 23, 3401-3409. doi:10.26355/eurrev_201904_17704. https://pubmed.ncbi.nlm.nih.gov/31081112/
7. Wang, Chaoyu, Fu, Wen, Zhang, Youju, Xu, Qiuran, Tong, Xiangmin. 2024. C-MYC-activated lncRNA SNHG20 accelerates the proliferation of diffuse large B cell lymphoma via USP14-mediated deubiquitination of β-catenin. In Biology direct, 19, 47. doi:10.1186/s13062-024-00488-9. https://pubmed.ncbi.nlm.nih.gov/38886753/
8. Wu, Xing-Cheng, Yan, Wei-Gang, Ji, Zhi-Gang, Zheng, Guo-Yang, Liu, Guang-Hua. 2019. Long noncoding RNA SNHG20 promotes prostate cancer progression via upregulating DDX17. In Archives of medical science : AMS, 17, 1752-1765. doi:10.5114/aoms.2019.85653. https://pubmed.ncbi.nlm.nih.gov/34900057/
9. Wang, Xiuli, Gu, Guomin, Zhu, Hongge, Abuduwaili, Kahaerjiang, Liu, Chunling. 2020. LncRNA SNHG20 promoted proliferation, invasion and inhibited cell apoptosis of lung adenocarcinoma via sponging miR-342 and upregulating DDX49. In Thoracic cancer, 11, 3510-3520. doi:10.1111/1759-7714.13693. https://pubmed.ncbi.nlm.nih.gov/33089952/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。